

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F (400/131)

Serial No.

10/665,951

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

1635

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	US-2002/0086356	03/30/01	Tuschl et al.			07/04/02
	*	US-2002/0151693	02/08/01	Breaker et al.			10/17/02
	*	US-2003/0064945	07/25/01	Akhtar et al.			04/03/03
	*	US 2003/0143732	08/30/02	Fosnaugh et al.			07/31/03
	*	US-2003/0186920	04/10/03	Sirios, Martin			10/02/03
	*	US-2004/0019001	07/26/02	McSwiggen et al.			01/29/04
	*	US-2004/0161844	11/04/03	Baker et al.			08/19/04
	*	US-2004/0209832	09/23/03	McSwiggen et al.			10/21/04
	*	US-2005/0020521	09/25/05	Rana, Tariq M.			01/27/05
	*	US-2005/0171039	05/11/04	McSwiggen et al.			08/04/05
	*	US-2005/0182005	05/13/04	Tuschl et al.			02/18/05
	*	US-2005/0227256	11/26/04	Hulvagner et al.			10/13/05

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	5,587,471	12/24/96	Cook et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F (400/131)

Serial No.

10/665,951

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

1635

	*	5,814,620	09/29/98	Robinson et al.			
	*	5,916,763	06/29/99	Williams et al.			
	*	5,998,148	12/07/99	Bennett et al.			
	*	5,998,206	12/07/99	Cowsert			
	*	6,214,805	04/10/01	Torrence et al.			
	*	6,506,559	01/14/03	Fire et al.			
	*	6,573,099	06/03/03	Graham et al.			
	*	6,710,174	03/23/04	Bennett et al.			
	*	6,824,972	11/30/04	Kenwrick et al.			
	*	7,022,828	04/04/06	McSwiggen et al.			
	*	7,078,196	07/18/06	Tuschl et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclas s	Translation	
							Yes	No
	1.	2,359,180	08/03/00	CA (Kreutzer et al.)				
	2.	1389637	08/05/02	EP (Klippel et al.)				
	3.	90/14090	11/29/90	WO (Gillespie et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F (400/131)

Serial No.

10/665,951

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

1635

4.	97/21808	06/19/97	WO (Robinson)				
5.	00/49035	08/24/00	WO (Sheen)				
6.	01/96584	12/20/01	WO (Mushegian et al.)				
7.	01/97850	12/27/01	WO (Siemeister et al.)				
8.	02/22636	03/21/02	WO (Bennett et al.)				
9.	03/044188	05/30/03	WO (Tei et al.)				
10.	04/029212	04/08/04	WO (Rana, Tariq M.)				
11.	04/043977	05/27/04	WO (Prakush et al.)				
12.	04/072261	08/26/04	WO (Li et al.)				
13.	04/090105	10/21/04	WO (Leake et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

14.	Alexeev et al., "Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," <i>Nature Biotechnology</i> , 18:43-47 (2000)
15.	Bellon et al., "4-Thio-oligo- β -D-ribonucleotides: synthesis of β -4'-thio-oligoridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase," <i>Nucleic Acids Research</i> , 21(7):1587-1593 (1993)
16.	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiology</i> , 1:34 (2001)
17.	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
18.	Braasch et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-F (400/131)	Serial No. 10/665,951
<p align="center">SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center">(Use several sheets if necessary)</p>		<p>Applicant: McSwiggen et al.</p>	
		<p>Filing Date: September 18, 2003</p>	<p>Group: 1635</p>

19.	Caplen, Natasha J., "RNAi as a gene therapy approach," <i>Expert Opin. Biol. Ther.</i> , 3(4):575-586 (2003)
20.	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," <i>Science</i> , 309, 1529-1530 (2005)
21.	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213 (2002)
22.	Futami et al., "Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against bcl-2," <i>Nucleic Acids Research Supplement</i> 2:251-252 (2002)
23.	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> , 543:51-54 (2003)
24.	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in <i>Drosophila</i> Cells," <i>Nature</i> 404:293-296 (2000)
25.	Hammond et al., "Post-Transcriptional Gene Silencing by Double-Stranded RNA," <i>Nature</i> , 2:110-119 (2001)
26.	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
27.	Hornung et al., "Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)
28.	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <i>Nature Biotechnology</i> , 23(4):457-462 (2005)
29.	Kawaski et al., "Uniformly Modified 2'-Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," <i>J. Med. Chem.</i> , 36, 831-841 (1993)
30.	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)
31.	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-F (400/131)	Serial No. 10/665,951
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 18, 2003	Group: 1635

32.	Mattick, John S., "The Functional Genomics of Noncoding RNA", <i>Science</i> , 309, 1527-1528 (2005)
33.	McCaffrey et al., "RNA interference in adult mice," <i>Nature</i> , 148, 38-39 (2002)
34.	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <i>J. Biol. Chem.</i> 268:14514-14522 (1993)
35.	Morvan et al., "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," <i>J. Med. Chem.</i> , 36, 280-287 (1993)
36.	Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," <i>Biochimica et Biophysica Acta</i> , 1576, 101-109 (2002)
37.	Opalinska et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Reviews Drug Discovery</i> , (1):503-514 (2002)
38.	Pavco et al., "Antitumor and Antimetastatic Activity of Ribozymes Targeting the Messenger RNA of Vascular Endothelial Growth Factor Receptors," <i>Clinical Cancer Research</i> 6:2094-2103 (2000)
39.	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:573-581 (1996)
40.	Thomson et al., "Activity of hammerhead ribozymes containing non-nucleotidic linkers," <i>Nucleic Acids Research</i> 21:5600-5603 (1993) (MAY BE REFERRED TO AS THOMPSON)
41.	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002)
42.	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <i>Journal of Biological Chemistry</i> , 278, 7108-7118 (2003)
43.	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci. USA</i> 90:6340-6344 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F (400/131)

Serial No.

10/665,951

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

1635

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.